BioStock

Prenumeration

BioStock: Alligator Bioscience awarded Orphan Drug Designation for mitazalimab

2023-05-25 08:45:00

Lund-based Alligator Bioscience continues to increase the value of its lead asset mitazalimab. The company recently announced receiving Orphan Drug Designation for the CD-40 antibody from the FDA. BioStock contacted Jonas Henningsen, VP Regulatory Affairs at Alligator, and CEO Søren Bregenholt, to learn more about what this means for the project.

Read the interview with Jonas Henningsen and Søren Bregenholt at biostock.se:

Alligator Bioscience awarded Orphan Drug Designation for mitazalimab - BioStock (https://www.biostock.se/en/2023/05/alligator-bioscience-awarded-orphan-drug-designation-for-mitazalimab/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden